Introduction: To avoid the need for
B35 weeks who were B6 months of age at randomization. Subjects were randomized 1:1 to 15 mg/kg of either liquid or lyophilized palivizumab administered via intramuscular injection every 30 days for a total of 5 injections. Safety was assessed based on serious adverse events (SAEs). ADA to palivizumab was assessed using blood collected at baseline and at a time point between study days 240 and 300.
Results: A total of 413 subjects were included in the analyses. The incidence of SAEs reported was 8.5% with liquid palivizumab and 5.9% with lyophilized palivizumab; none were deemed drug-related. The reported SAEs were consistent with expected conditions in this pediatric age group; there was no increase in respiratory syncytial virus (RSV) disease with liquid palivizumab. At study days 240-300, antipalivizumab antibodies were detected in none of the subjects in the liquid palivizumab group and in 1 subject in the lyophilized group.
The true ADA percent positive, based on the upper limit of the 95% confidence interval (CI), was \1.5% for both treatments combined.
Conclusion:
The frequency of detection of ADAs was low. The true ADA percent positive for both treatment groups combined based on the upper limit of the 95% CI was \1.5%. The type and frequency of SAEs reported were as expected, and there was no evidence of an increase in RSV disease with liquid palivizumab. MedImmune; Gaithersburg, MD, USA) was the first product used for preventing severe RSV disease and required a 4-h intravenous infusion.
Palivizumab (MedImmune), an F-proteinspecific humanized monoclonal antibody, was an advance in RSV prevention, as it could be given intramuscularly [3] . Palivizumab, first licensed in the United States in 1998, is indicated for the prevention of serious lower respiratory tract disease due to RSV in children at high risk of RSV disease [4] . It is currently licensed in more than 80 countries [5] . The efficacy of palivizumab has been established in three randomized, placebo-controlled studies [6] [7] [8] . Initially, palivizumab was available only in a lyophilized formulation that required reconstitution with sterile water to a concentration of 50 or 100 mg/mL [9] . To avoid the need for reconstitution, a liquid formulation of palivizumab was developed [9] . 
METHODS

Subjects
The study included medically stable children with chronic lung disease of prematurity who were B24 months of age at randomization and children born prematurely with a gestational age of B35 weeks who were B6 months of age at randomization. Children were excluded if they received lyophilized palivizumab, IGIV, or other RSV-specific monoclonal antibody within 3 months before randomization, were receiving mechanical ventilation at the time of study entry, had congenital heart disease, acute respiratory or other acute infection or illness, a life expectancy of \6 months, or had a mother diagnosed with human immunodeficiency virus, unless the child had been proven to not be infected. each study subject's parent or legal guardian before study entry.
Study Drug
Study medication was administered via intramuscular injection every 30 days during the RSV season, for a total of 5 injections. All subjects were scheduled to receive 5 injections.
Liquid palivizumab was supplied in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile, preservative-free liquid, formulated with 25 mM histidine and 1.6 mM glycine. Lyophilized palivizumab was supplied in sterile vials containing 100 mg of sterile lyophilized product that when formulated contained 25 mM histidine, 1.6 mM glycine, and 3% mannitol. Lyophilized palivizumab required reconstitution with 1 mL of sterile water for injection to yield palivizumab at a concentration of 100 mg/mL. Liquid and lyophilized palivizumab were similar in formulation with the exception of the excipients.
Study Design
This phase 4, randomized, double-blind, multicenter study enrolled subjects over 2 RSV The study was conducted in a double-blind manner with the medical monitor, statistician, project management, site monitors, data management, subjects' parents, and the clinical site staff blinded to study treatment assignment throughout the study. An independent monitor who only received pharmacy records and the investigational agent manager at the study site were the only people with access to information that identified a subject's treatment allocation.
Neither individual was to reveal to anyone the treatment arm to which a subject was assigned.
The study drug was supplied to the pharmacy as open-label vials of liquid or lyophilized palivizumab. The investigational agent manager prepared the study drug and dispensed it in identically appearing syringes, labeled using the subjects' initials.
Safety
Safety was assessed based on serious adverse events (SAEs). Subjects were monitored through study day 150 or until the resolution of any serious events, whichever was longer. SAEs were defined as those that resulted in death, were life-threatening, led to hospitalization, or prolongation of an existing hospitalization.
SAEs were graded by severity (mild, moderate, severe, or life-threatening) and by relationship to study drug (none, remote, possible, probable, or definite) as determined by the principal investigator.
Antidrug Antibodies
ADA to palivizumab was assessed using blood collected at baseline before the first dose of study medication and at 1 time point between study days 240 and 300 (approximately 4-7 months after the last dose of study medication).
Antipalivizumab antibody analyses were performed at PPD (Richmond, VA, USA) using a validated enzyme-linked immunosorbent assay (ELISA) (developed by MedImmune) [14] . Controls were prepared by 
Statistical Analyses
The safety analysis included all subjects who received any study medication. The ADA analysis included subjects who received C2 doses of study medication and had C1 blood sample collected. The sample size calculation was based on findings from the pivotal phase 3 study [6] 
RESULTS
Subjects
A total of 417 subjects were randomized into the study across the 51 sites in the United States, and 413 subjects were followed and included in all of the safety analyses; 4 subjects from 1 site were excluded from the analyses because the site did not provide any additional information or data regarding the subjects other than the fact that they received all 5 doses of palivizumab. Of the 413 subjects, 211 were randomized into the liquid palivizumab group and 202 were randomized into the lyophilized palivizumab group. Overall, 26/413 (6.3%) subjects did not complete the study. The most common reasons for not completing the study were lost to follow-up Demographic and baseline characteristics, including age, gender, race, and weight, were similar between the liquid and lyophilized palivizumab groups (Table 1) .
Safety
The majority of subjects in both study groups Table 2 ). The reported SAEs were consistent with common conditions in this pediatric age group. The most common SAEs (i.e., those occurring in C2 subjects) were bronchiolitis, gastroenteritis, respiratory distress, viral infection, cleft lip, and inguinal hernia ( Table 2 ). The incidence of bronchiolitis was 2.8% (6/211) in the liquid palivizumab group and 1.5% (3/202) in the lyophilized palivizumab group. One subject in the lyophilized palivizumab group died of asphyxia during the study, but the death was deemed not related to the study medication by the study investigator. None of the SAEs were determined by the investigators to be related to study medication.
By system organ class, 2 system organ classes had Of the 9 events of bronchiolitis, 7 were tested locally for RSV (liquid, n = 5; lyophilized, n = 2) and all 7 were negative. A single event of bronchopneumonia (in the liquid palivizumab group) was tested locally and was negative for RSV. Both events of viral infection were negative for RSV based on local testing.
The events of respiratory, thoracic and mediastinal disorders reported in the lyophilized palivizumab group were respiratory distress (2 subjects), and apnea, asphyxia, and dyspnea (each in 1 subject). The SAE of asphyxia resulted in death (described above).
The remaining events occurred sporadically throughout dosing; all required hospitalization and resolved within 2-10 days after treatment. The events of apnea, dyspnea, and asphyxia were tested locally for RSV and all were negative. CLD Chronic lung disease, SD standard deviation
Antidrug Antibodies
At baseline, none of the subjects exhibited antipalivizumab antibodies. From study days 240-300, antipalivizumab antibodies were detected in none of the subjects in the liquid palivizumab group and in 1/188 subject (0.5%) in the lyophilized palivizumab group (at Table 2 B6 months who were born B35 weeks gestational age [12] . In that study, the percentages of infants with SAEs were similar (liquid, 3.3%; lyophilized, 2.6%) [12] . The type and frequency of SAEs reported were similar between the liquid and lyophilized palivizumab groups [12] . The incidence of bronchiolitis SAE reported was also similar between the 2 groups (liquid, 2.8%; lyophilized, 1.5%).
The ADA results in the present and previous studies were based on positive palivizumab antibodies using an ELISA, which is limited in its ability to detect antipalivizumab antibodies in the presence of palivizumab [4] . In the present study, the true ADA percent positive for both treatment groups combined based on the upper limit of the 95% CI was at most 1.5%.
The 0.5% observed ADA percent positive (with an upper limit of the 95% CI of 2.9%) for lyophilized palivizumab reported in the present study was consistent with the 1.2% observed ADA percent positive reported in a previous phase 3 trial of lyophilized palivizumab in 1,502 children [6] . In another previous trial of highrisk preterm children B24 months of age, the ADA percent positive was 0.3% for both palivizumab formulations combined [4] . It is possible that the ADA percent positive in both study arms of the present study could have been higher had the current drug-tolerant electrochemiluminescence (ECLA) assay been used. However, 2 studies of liquid palivizumab recipients that used an ECLA to determine ADA also demonstrated ADA percents positive of 1.1% and 1.5% [4] . 
